Immunovant Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2022 | $45.7M | $515.6M | $493.8M |
| FY2023 | $43.3M | $405.8M | $376.5M |
| FY2024 | $48.6M | $666.4M | $635.4M |
| FY2025 | $68.8M | $776.2M | $714.0M |
| FY2026 | $104.4M | $957.0M | $902.1M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2022 | $45.7M | $515.6M | $493.8M |
| FY2023 | $43.3M | $405.8M | $376.5M |
| FY2024 | $48.6M | $666.4M | $635.4M |
| FY2025 | $68.8M | $776.2M | $714.0M |
| FY2026 | $104.4M | $957.0M | $902.1M |